EVALUATION OF CONCURRENT ENDOMETRİAL CANCSER İN PATİENTS WİTH ENDOMETRIAL HYPERPLASIA; 10 YEARS EXPERIENCE AS A TERTİARY CENTER
| العنوان: | EVALUATION OF CONCURRENT ENDOMETRİAL CANCSER İN PATİENTS WİTH ENDOMETRIAL HYPERPLASIA; 10 YEARS EXPERIENCE AS A TERTİARY CENTER |
|---|---|
| المؤلفون: | Ece Uslu, Tufan Oge, Duygu Kavak Comert, Yusuf Çakmak, Özgür Aydın Tosun |
| المصدر: | Volume: 50, Issue: 4 222-226 Zeynep Kamil Tıp Bülteni |
| بيانات النشر: | Medical Bulletin of Zeynep Kamil, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, medicine.diagnostic_test, business.industry, Endometrial cancer, Gynecologic oncology, Hyperplasia, medicine.disease, Gastroenterology, Endometrial hyperplasia, Health Care Sciences and Services, Atipili endomertial hiperplaziler,Atipisiz endometrial hiperplazi,Endometrial kanser, Internal medicine, Obstetrics and Gynaecology, medicine, Atypia, Surgery, Atypical endometrial hyperplasia,Simple endometrial hyperplasia,Endometrial cancer, Pediatrics, Perinatology, and Child Health, Sağlık Bilimleri ve Hizmetleri, Simple Endometrial Hyperplasia, business, Atypical Endometrial Hyperplasia, Endometrial biopsy |
| الوصف: | ÖZETAmaç: Cerrahi tedavi uygulanan endometrial hiperplazili hastalarda eşzamanlı endometrial kanser insidansını belirlemeyi amaçladık.Gereç ve yöntem: Çalışmamız retrospektif olarak dizayn edildi. 2007 - 2017yılları arasında Eskişehir Osmangazi Üniversitesi (ESOGÜ) jinekolojik Onkolojibölümünde endometrial biyopsi ile endometrial hiperplazi (EH) tanısı alan vecerrahi tedavi uygulanan hastaların tıbbi kayıtları incelenerek çalışmaoluşturuldu. Endometrial örnekleme sonucu endometrial hiperplazili 522 hastanınverileri değerlendirildi. 187 hasta medikal tedavi uygulandığı için, 35 hastatıbbi kayıtları yetersiz olduğu için ve15 hasta endometrial kanser şüphesi olduğu için çalışma dışı bırakıldı.Çalışmaya endometrial hiperplazili 285 hasta dahil edildi.Bulgular: Çalışmaya alınan 285 hastanın 64'ü (% 22.4) basit hiperplazi, 31'i (%10.8) basit atipili hiperplazi, 72'si (% 25.2) kompleks hiperplazi ve 118'i (%41.4) kompleks atipili hiperplazi idi. Histerektomi spesmenlerininincelenmesiyle 84 (% 29.4) hastada endometrial patoloji izlenmezken , 36hastada (% 12.6) endometrial kanser, 165 hastada (% 57.8) endometrialhiperplazi bulduk. Basit hiperplazide 1 (% 1,5) hastada endometrial kanserbulduk.Basit atipili hiperplazide 1 (% 3,2) hastada endometrial kanser tespitedildi. Kompleks hiperplazide 6 hastada(% 8.3) endometrial kanser vardı. Kopleks atipili hiperplazide 28 (% 23,7) hastada endometrial kanser tespit edildi. 2014 DünyaSağlık Örgütü sınıflandırma sistemine göre, eş zamanlı endometrial kanseroranları atipili endometrial hiperplazide % 19.4, atipi olmayan endometrial hiperplazide % 5.1 olarak tespitedildi.Sonuç: Basit hiperplazide eşzamanlıendometrial kanser oranı% 5.1, bu oran kompleks hiperplazide % 8,3 olarakbulundu. Atipi olmayan endometrial hiperplazili hastaların tedavisinde medikal tedavi seçilecekse bu oranlar göz önünde bulundurulmalıdır.Endometrialhiperplazi yönetiminde endometrialkanser için tüm risk faktörlerinin detaylı değerlendirilmesi önerilir. Objective: we aimed to determine the incidence of simultaneous endometrial cancerin patients with endometrial hyperplasia who underwent surgical treatment.Materialand method: Our studywas designed retrospectively.The medical data of patients who wasdiagnosed endometrial hyperplasia(EH) bythe endometrial biopsy and accepted surgical treatment were examined and collected between 2007 -2017 at the gynecologic oncology depertmant of Eskişehir Osmangazi University(ESOGÜ).The data of 522 patients with endometrial hyperplasia as a result of endometrialsampling were evaluated. Due to 187 patients received medicaltreatment, 35 patients lacked medical data and 15 patients suspected endometrial CA were excluded from the study.Atotal of 285 patients with endometrial hyperplasia were included in the study.Result:Of the 285 patients included in the study, 64 (22.4%) were simple hyperplasia,31 (10.8%) were simple atypia hyperplasia, 72 (25.2%) were complex hyperplasiaand 118 (41.4%) were complex atypia hyperplasia. Endometrialhyperplasia could not be detected in 84 (29.4%) patients after a finalpathology. We found endometrial cancer in 36 (12.6%) patientsand endometrial hyperplasia in 165 (57.8%) patients. We found 1 (1.5%) patientEC in simple hyperplasia. EC was detected in 1 (3.2%) patient in SAH. 6patients (8.3%) had EC in CH. 28 (23.7%) EC’s were detected in patients withCAH. According to the 2014 WHO classification system,Concurrent endometrial cancer rates were determined as AEH 19.4% and EH without atypia was 5.1%.Conclusion: Concurrent EC ratio in simple hyperplasia was5.1% this rate was found to be 8.3 % inCH. Management of patients with endometrialhyperplasia without atypia If medical treatment is to be chosen, these ratesshould be considered and it is recommended to consider all risk factors for EC. |
| وصف الملف: | application/pdf |
| تدمد: | 1300-7971 2148-4864 |
| DOI: | 10.16948/zktipb.557389 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e8df303ed2a21914d9da14976e42c58 https://doi.org/10.16948/zktipb.557389 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1e8df303ed2a21914d9da14976e42c58 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13007971 21484864 |
|---|---|
| DOI: | 10.16948/zktipb.557389 |